• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Top in hem/onc: Multiple myeloma salvage therapy; revaccination guidance after cell therapy

by | Nov 17, 2022 | Uncategorized

Patients with multiple myeloma who relapse after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy may benefit from “subsequent T-cell redirection,” according to researchers.The findings support clinical trials investigating the sequence of...

Tecvayli Is a Quicker and ‘More Convenient’ Treatment for Myeloma, But Limited Hospital Space Highlights the Need for Outpatient Therapies

by | Nov 17, 2022 | Uncategorized

Source: Cure Today articles Tecvayli, which was recently approved for pretreated relapsed/refractory myeloma, is a “much more convenient” treatment option than CAR-T cell therapy, one expert said. Read More

Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma

by | Nov 16, 2022 | Uncategorized

Despite being behind the curve for adoption of immunotherapy, the field of multiple myeloma has witnessed monumental advances in patient survival with the use of novel agents, according to a speaker at Chemotherapy Foundation Symposium.The need for novel...

FDA to Review Aphexda in the Transplant Setting for Patients with Multiple Myeloma

by | Nov 13, 2022 | Uncategorized

Source: Cure Today articles Aphexda was well tolerated and helped the majority of patients collect enough cells to go to transplant, study results showed. Read More

Blenrep Misses Main Study Goal for Patients with Relapsed/Refractory Multiple Myeloma

by | Nov 8, 2022 | Uncategorized

Source: Cure Today articles Blenrep did not meet its progression-free survival endpoint in a phase 3 clinical trial for patients with relapsed or refractory multiple myeloma. Read More

Salvage therapies may benefit patients with multiple myeloma who relapse after CAR-T

by | Nov 8, 2022 | Uncategorized

Salvage therapies appeared to maintain clinical activity among patients with relapsed/refractory multiple myeloma who relapsed after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, according to study results.The findings, published in...
« Older Entries
Next Entries »

Recent Content

  • Talquetamab and Teclistamab Achieve Deep, Durable Responses in Patients With Relapsed, Refractory Multiple Myeloma
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
  • Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
  • Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma
  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT